Using the new HPV vaccines in clinical practice.
Gardasil, a vaccine against human papillomavirus (HPV), recently became available in the United States for use in girls and women 9 to 26 years of age. A second HPV vaccine, Cervarix, is under development. These vaccines constitute the most significant development in cervical cancer prevention in the last 60 years, having the potential to reduce the incidence of cervical cancer by up to 70%
Widdice
Lea E
LE
Division of Adolescent Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA. lea.widdice@cchmc.org
Kahn
Jessica A
JA
D000293:Adolescent; D000328:Adult; D002648:Child; D003218:Condylomata Acuminata / Q000517:prevention & control / Q000821:virology; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology; D014765:Viral Vaccines / Q000008:administration & dosage*
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; D014765:Viral Vaccines